Skopos Bio has raised $12 million in seed funding to advance a nuclear-science-backed therapy for hard-to-treat cancers. Advised on by EM Advisory, the round was backed by venture capital firms Tenmile, Tin Alley Ventures and US-based Yosemite.
Skopos Bio was founded by three scientists from Melbourne’s Peter MacCallum Cancer Centre: Michael Hofman, Luc Furic, and Mohammad Haskali. The company is developing targeted radioactive molecules to diagnose and treat cancer, initially focusing on hard-to-treat prostate cancer.
The funding will support the Melbourne oncology startup with research and development as the company progresses towards human clinical trials.
EM Advisory advised the founders of Skopos Bio on its spinout from the Peter MacCallum Cancer Centre and $12 million seed funding round. The consulting firm helped the founders negotiate with their employer (Peter MacCallum Cancer Centre) and incoming investors, and navigate the commercial arrangements needed to establish an independent business and secure funding for its development.
“Our role was to help the founders navigate negotiations with their employer and investors as they established the company,” said Natasha Mandie, Founder and Managing Director of EM Advisory. “This round brings together Australian and international backing to support Skopos Bio’s science and its next stage of development.”
Founded in 2011, EM Advisory helps growth-stage and mid-market companies with growth, capital raising, ownership succession and M&A transactions. Earlier this year, the firm also was involved with deals in the technology and sports sectors, among others.